N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease

European Respiratory Journal

Volumn 21, Issue 5, 2003, Pages 795-798

  Gerrits, C M J M ^a   Herings, Ron M C ^a,b   Leufkens, H G M ^a   Lammers, J W J ^c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^c Heart Lung Institute Utrecht   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Hospitalisation; Mucolytics; N acetylcysteine; Pharmacoepidemiology

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; MUCOLYTIC AGENT; NEDOCROMIL; STEROID; XANTHINE DERIVATIVE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEATH; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RISK MANAGEMENT;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPECTORANTS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 0037718518     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00063402     Document Type: Article

References (26)

1. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1256-1276.
2. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53: 129-136.
3. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
4. Fabbri L, Beghe B, Caramori G, Papi A, Saetta M. Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease. Thorax 1998; 53: 803-808.
5. Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000; 117: 662-671.
6. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copennhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-1535.
7. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997; 156: 341-357.
8. Gallon AM. Evaluation of nebulised acetylcysteine and normal saline in the treatment of sputum retention following thoracotomy. Thorax 1996; 51: 429-432.
9. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001; 322: 1-6.
10. Del Donno M, Olivieri D. Mucoactive drugs in the management of chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1998; 53: 714-719.
11. Grandjean EM, Berthet PH, Ruffmann R, Leuenberger P. Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis. Pharmacol Res 2000; 42: 39-50.
12. Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16: 253-262.
13. Herings RM, de Boer A, Stricker BH, Leufkens HG, Porsius A. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345: 1195-1198.
14. Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998; 158: 1108-1112.
15. Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta 2-agonists. Am J Epidemiol 1996 15; 144: 1161-1169.
16. Garrett JE, Lanes SF, Kolbe J, Rea HH. Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity. Thorax 1996; 51: 1093-1099.
17. Van Ganse E, Kaufman L, Derde MP, Yernault JC, Delaunois L, Vincken W. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J 1997; 10: 2216-2224.
18. Hirshman JV. Do bacteria cause excerbations of COPD? Chest 2000; 118: 193.
19. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8: 1333-1338.
20. Riise GC, Larsson S, Larsson P, Jeansson S, Andersson BA. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy? Eur Respir J 1994; 7: 94-101.
21. Riise GC, Qvarfordt I, Larsson S, Eliasson V, Andersson BA. Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration 2000; 67: 552-558.
22. Tsukagoshi H, Shimizu Y, Iwamae S, et al. Evidence of oxidative stress in asthma and COPD: potential inhibitory effect of theophylline. Respir Med 2000; 94: 584-588.
23. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ 1997; 315: 1151-1154.
24. Johnston SC. Identifying confounding by indication through blinded prospective review. Am J Epidemiol 2001; 154: 276-284.
25. Geijer RM, Thomas S. Drug treatment of chronic obstructive lung disease. Med Tijdschr Geneeskd 1996; 140: 761-765.
26. Decramer M, Dekhuijzen PNR, Troosters T, et al. The BRONCUS-trial Committee. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. Eur Respir J 2001; 17: 329-336.